Familial dysbetalipoproteinemia (or type III hyperlipoproteinemia) is characterized by the presence of abnormal, cholesteryl ester-rich fl-very low density lipoproteins (fl-VLDL) in the plasma. Subjects with typical dysbetalipoproteinemia are homozygous for an amino acid substitution in apolipoprotein (apo-) E at residue 158 and have defective apo-E-mediated binding of both pre-ft-VLDL and f8-VLDL to apo-B,E(LDL) (or LDL) receptors (1988. Chappell, D. A., J. Clin. Invest. 82:628-639). To understand the effect of substitutions in apo-E at sites other than residue 158, nine dysbetalipoproteinemic (dys-f,) subjects who were eitherlbomozygous or heterozygous for substitutions in apo-E at atypical sites were studied.
Introduction
Familial dysbetalipoproteinemia (or type III hyperlipoproteinemia) is characterized by the presence of abnormal, cholesteryl ester-rich fl-migrating very low density lipoproteins (fi-VLDL) in the plasma (1) . Apolipoprotein (apo-) E was first implicated in the pathogenesis of dysbetalipoproteinemia when Havel and Kane reported the abundance of apo-E in jects (2) . Later, by isoelectric focusing, Utermann et al. showed that apo-E from dys-$ subjects was abnormal (3) . There are three common isoforms of apo-E, (E2, E3, and E4), which differ in isoelectric focusing positions as a result of substitutions involving charged amino acids (4, 5) . Apolipoprotein E4 differs from normal apo-E3 by the substitution of arginine for cysteine at residue 1 12 (Cys, 12 --Arg), whereas apo-E2 differs from apo-E3 by the substitution of cysteine for arginine at residue 158 (Arg,58 -. Cys) (5, 6) . Most dys-fl subjects are homozygous for the substitution at residue 158 (ArgI58 -O Cys) and have an E2/2 phenotype (6, 7). These subjects are said to have typical dysbetalipoproteinemia, which is inherited as an autosomal recessive trait. Heterozygous individuals with the E3/2 phenotype rarely develop dysbetalipoproteinemia. However, dys-,B subjects with E3/3, E3/2, or E2/1 phenotypes have been described (8) (9) (10) (11) (12) . In addition, a variety of amino acid substitutions may cause the same phenotype.
Apolipoprotein E binds to apo-B,E(LDL) (or LDL) receptors with high affinity. All ofthe known substitutions in apo-E that are associated with dysbetalipoproteinemia disrupt this binding to some extent (for review, see reference 1) . Schneider et al. showed that apo-E isolated from dys-f subjects may have either very defective or nearly normal receptor binding compared to the binding of apo-E from normal individuals (13). Normal apo-E3, purified and reconstituted into phospholipid complexes, has 50-, 5-, 2.5-, or 2-fold higher affinity than does apo-E with a substitution at residue 158, 142, 146, or 145, respectively (1, 5, 8) .
The severity of the binding defect caused by the various substitutions in apo-E does not correlate with the severity of dysbetalipoproteinemia (6, 13) . The vast majority of individuals homozygous for the most defective form of apo-E do not develop clinically significant hyperlipidemia. These individuals have fl-VLDL in their plasma but have normal or even low cholesterol concentrations (6, (14) (15) (16) . Clearly, factors other than defective binding of apo-E to apo-B,E(LDL) receptors are important in the expression of this disease. These factors include obesity, the inheritance ofhypertriglyceridemia or familial combined hyperlipidemia, and the effects of estrogen or thyroid hormones (17) (18) (19) (20) (21) (22) (23) .
The mechanism of fl-VLDL formation is partially understood. Pre-f3-VLDL appear to be precursors of fl-VLDL.
Pre-fl-VLDL are larger, more triglyceride-rich particles with higher flotation rates than fl-VLDL and may be converted to /3-VLDL during lipolysis (24) (25) (26) (27) (28) . Accelerated lipolysis induced by intravenous heparin causes the formation of f-VLDL and a decrease in pre-3-VLDL in subjects with either normal or abnormal apo-E (25) (26) (27) (28) . Recently, I showed that pre-f-VLDL from typical dys-f subjects had extremely low affinity for apo-B,E(LDL) receptors (27) . In these subjects, defective binding of pre-3-VLDL to receptors could result in delayed receptor-mediated clearance and increased conversion to f-VLDL during lipolysis. Their f-VLDL had 68-fold higher binding affinity than their pre-f-VLDL (27) . However, the binding of f-VLDL from the typical dys-f subjects was defective when compared with heparin-induced f-VLDL from subjects homozygous for normal apo-E3 (27) . These data suggest that defective binding of both pre-o-VLDL and 3-VLDL to receptors may be involved in the formation and accumulation of f-VLDL in typical dys-0 subjects.
In this study, dys-f subjects who were either heterozygous or homozygous for amino acid substitutions in apo-E at atypical sites (residue 142, 145, or 146) are defined as having atypical dysbetalipoproteinemia. To understand the role of atypical apo-E mutations in the pathogenesis of dysbetalipoproteinemia, the chemical composition, apolipoprotein content, and receptor binding affinities of their d < 1.006 g/ml lipoproteins were determined. In addition, cholesterol-fed rabbits and cholesterol-fed dogs, animal models in which there is 3-VLDL accumulation (29) (30) (31) , were studied to see whether their d < 1.006 g/ml lipoproteins resembled those from typical or those from atypical dys-f subjects.
Methods

Human subjects
The subjects studied are described in Table I . 10 subjects were members of a single family (family A.) in which dysbetalipoproteinemia was inherited as an autosomal dominant trait through four generations (9, 10). All family members had an E3/3 phenotype. However, family members with dysbetalipoproteinemia were heterozygous for normal apo-E3 and a double mutation in apo-E, that resulted in no net change in the charge (Arg142 -Cys, Cys,12 -Arg) (10) . Family members who did not have dysbetalipoproteinemia had a double pre-0 pattern on agarose electrophoretograms of their VLDL (9) . Subject 3 was taking gemfibrozil (600 mg twice daily) at the time of this study. The other dys-,B subjects were not taking medication. Subjects 11 and 12 had an E2/2 phenotype and were homozygous for the Arg145 _-Cys substitution in apo-E (5, 32). Subject 13 had an E3/2 phenotype and had had a dys-f profile (8) ; however, at the time of this study he had a type V lipoprotein phenotype as determined by agarose electrophoresis and analytical ultracentrifugation (data not shown). All subjects gave written informed consent for the study; the study was approved by the Human Research Committee at University of California, San Francisco.
Lipoprotein preparation
Subjects fasted for 14 h before blood sampling. Blood samples were adjusted to contain 1 mg EDTA (sodium salt)/ml and were immediately placed on ice. The plasma was separated from the cells by centrifugation at 2,000 rpm for 15 min at 4°C. To prevent proteolytic degradation, the plasma was adjusted to contain 10,000 U of aprotinin/liter (Mobray Chemical Corp., New York), I mM benzamidine. I mM PMSF, and 80 mg of gentamicin/liter (Sigma Chemical Co., St. Louis, MO) (33) .
Isolation of lipoproteins by ultracentrifiigation. The d < 1.006 g/ml lipoproteins and LDL were isolated from the plasma by ultracentrifugation (34) . The Sf > 100, Sf 60-100, and Sf 20-60 flotation fractions were isolated according to the method of Lossow et al. (35) .
Peivikon block electrophoresis. Pre-3-VLDL and 3-VLDL were isolated by Pevikon block electrophoresis of the total d < 1.006 g/ml lipoproteins (Mercer Consolidated Corp., Yonkers, NY) (36, 37) . Human LDL were used as a reference for ,B-electrophoretic mobility to aid in determining the fractionation of pre-O-migrating and f-migrating lipoproteins on each Pevikon block (27 (39) . Cholesteryl ester concentration was estimated by using gasliquid chromatography (27) . The relative apolipoprotein content of lipoproteins was determined using electrophoresis on 5-20% SDSpolyacrylamide gradient gels stained with Coomassie blue R-250 (27, 40) . Coomassie blue-stained gels were scanned at 600 nm on a CS-930 scanner (Shimadzu, Kyoto, Japan). Silver staining was performed on some gels (41) . The apo-E phenotypes were determined as described (42) . The molecular weights of lipoproteins were estimated from their average molecular volume assessed by electron microscopy (43) and by the partial specific volumes of the chemical constituents (27, 44) . The electrophoretic mobility of each fraction was determined by 1% agarose electrophoresis (Corning, Palo Alto. CA) (27) .
Fibroblast binding assays
Normal human fibroblasts were grown in 35-mm petri dishes (45) . Lipoproteins were iodinated (sp act 200-500 cpm/ng) by the iodomonochloride method (46) . The ability of d < 1.006 g/ml fractions at various concentrations to compete for the binding of 'I51-LDL at 2 pg of protein/ml at 4°C was determined in duplicate (45) . Binding data were analyzed by nonlinear least-squares curve fitting (allfit) (27, 47, 48) .
Monoclonal antibodies that specifically inhibit binding by apo-E (1 D7) or apo-B 100 (4G3) to the apo-BE(LDL) receptor were generously provided by Dr (49, 50) . The monoclonal antibody MB47, which specifically inhibits the binding of apo-B 100, was generously provided by Dr. S. Young, of the Gladstone Foundation Laboratories (51) . The ability of 1D7. 4G3, or MB47 to inhibit the binding of '25I-VLDL fractions to cultured human fibroblasts at 4°C was determined by incubating medium containing 5-20 pg of antibody/ml and 1 jug of '251-VLDL/ml for I h at 25°C before use in the binding assays (27, 52) .
Nonspecific binding was defined as the amount bound in the presence of 100-fold excess of the corresponding unlabeled lipoprotein fraction. All measurements were performed in duplicate.
A nimnal studies. Rabbits and foxhounds were fed a high-cholesterol.
high-saturated-fat diet (31) . The plasma cholesterol concentration in these animals was > 1,000 mg/dl. Pre-O-VLDL and O-VLDL were isolated by using the same method described above for human lipoproteins.
Results
The dys-f subjects studied were 0-45% above their ideal body weight (Table I) . Members of family A. who did not have dysbetalipoproteinemia had a double pre-0 pattern; furthermore, three were hypercholesterolemic. The plasma cholesterol and triglyceride concentrations in the dys-f subjects ranged from minimally to markedly elevated.
Characterization (?fd < 1.006-g/ml lipoproteins. Lipoproteins were isolated by Pevikon block electrophoresis of the total d < 1.006-g/ml fraction and by sequential ultracentrifugal flotation of whole plasma. The relative content of pre-0-VLDL and O-VLDL in the d < 1.006-g/ml fractions as as- sessed by agarose electrophoresis (data now shown) was similar to that of corresponding fractions from the typical dys-,B subjects studied previously (27) . The total d < 1.006 g/ml fractions in all dys-f3 subjects contained a prominent (3-migrating band and a less prominent pre-,3-migrating band. The pre-j3-VLDL predominated in the Sf > 100 fraction, whereas the ,B-VLDL predominated in the Sf 20-60 fraction. Using agarose electrophoresis, the d < 1.006-g/ml lipoproteins from atypical and typical dys-,B subjects were indistinguishable. Subject 13 was included in the study because he had had a dys-# profile.
However, at the time of this study, he had a type V profile, as determined by agarose electrophoresis and analytical ultracentrifugation (data not shown).
The chemical compositions and calculated average molecular weights of the d < 1.006 g/ml lipoproteins are listed in Table II . These data are similar to those for corresponding lipoproteins from typical dys-,3 subjects reported previously (27) . The pre-f3-VLDL were larger and more triglyceride-rich than the smaller, more cholesteryl ester-rich #l-VLDL. The average calculated density ofthe pre-,B-VLDL (0.977 g/ml) was less than that ofthe ,B-VLDL (0.994 g/ml). The chemical compositions and molecular weights of the Sf > 100, Sf 60-100, and Sf 20-60 fractions reflected their content of pre-,B-VLDL and ,B-VLDL.
The relative apolipoprotein content of the d < 1.006 g/ml fractions was estimated by scanning densitometry of SDSpolyacrylamide gel electrophoretograms ( Fig. 1 and Table III ). In Fig. 1 A, the d < 1.006 g/ml fraction from representative dys-# subjects had relatively more apo-E and apo-B48 (lanes 2 and 3) than did members of family A. without dysbetalipoproteinemia (lane 1). The Sf 20-60, Sf 60-100, and Sf > 100 fractions from representative dys-fl subjects also had increased amounts ofapo-E and apo-B48 ( Fig. 1 B and Table III) relative to the unaffected subjects. The d < 1.006 g/ml lipoprotein fractions from atypical dys-,B subjects had higher apo-E to total apo-C (E:C) ratios than those found in corresponding lipopro- Family Members also had fivefold higher affinity than did LDL from a normal o~~it y-Osubject (Fig. 2) .
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The d < 1.006 g/ml lipoproteins from dys-# subjects with \s\S the different substitutions in apo-E were further fractionated 0o
by Pevikon block electrophoresis, and the ability of these fractions to compete for the binding of '251-LDL to cultured human fibroblasts at 40C is shown in Fig. 3 (Fig. 3 , B and C, mily A. with dys-# who had a substitution in apo-E at residue respectively).
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The ability of the Sf > 100, Sf 60-100, and Sf 20-60 fractions to compete for the binding of '25I-LDL to fibroblasts at 40C is shown in Fig. 4 . Each of these fractions, whether isolated from subjects with an amino acid substitution in apo-E at s from typical dys-f subjects (Table III) . A band with the residue 142, 145, or 146, had higher affinity for apo-B,E(LDL) e apparent molecular weight as did albumin was present in receptors than did LDL from normal subjects (Fig. 4 , A-C, e samples (Fig. 1) 11 Values shown from typical dys-,B subjects have been reported previously (27) .
these lipoproteins compared with that of LDL (EC was apparent when binding affinity was expresses basis.
In an effort to avoid artifacts associated with of lipoproteins, receptor binding studies using v were performed (Fig. 5) . Fresh whole plasma wg two consecutive days. Whole plasma from atypic jects 3 or 4 had, on average, sevenfold higher rect affinity than did the whole plasma from two noi E3/3 subjects; EC50 = 14 vs. 100 ,gg protein/ml (a experiments). These data reflect the average rece affinity ofall lipoproteins in the whole plasma anc the average affinity of lipoproteins in atypical was higher than that in normal plasma.
Apolipoprotein E was responsible for the m; binding of all d < 1.006 g/ml lipoprotein frat apo-B,E(LDL) receptor. Monoclonal antibodi MB47, which specifically block apo-Bl00-medi; inhibited 0-35% of the binding of the '25I-VLDL studied (i.e., pre-#-VLDL, f3-VLDL, and the 60-100, and Sf 20-60 fractions). However, the inhibited > 90% of '251I-LDL binding. In contrast antibody 1D7, which specifically inhibits ape binding, inhibited 60-90% of the binding of th subfractions. Comparison of Sf> 100 and Sf 20 showed no shift from apo-E-mediated to apo-B 1 binding. These studies were performed on two c rate occasions and used pre-f3-VLDL, f3-VLDL, 60 -100, or Sf 20-60 fractions from subjects 3, 4 had a substitution in their apo-E at residue 142c
Studies in cholesterol-fed rabbits and cholest Cholesterol-fed rabbits and cholesterol-fed dog models in which there is 13-VLDL accumulatic they do not have a mutation in apo-E. pg Protein/ml Figure 5 . Competition of whole plasma for the bindini '251I-LDL to fibroblasts at 4VC. Fresh whole plasma (cc mg/ml EDTA, sodium salt) from atypical dys-fl subjec = 7.5 ug protein/ml), atypical dys-f subject 4 (-, EC50 tein/ml, or normolipidemic E3/3 subjects (a, EC50 = E ml or u, EC50 = 97 jig protein/ml) was used in the con dicated. lipoproteins from cholesterol-fed rabbits and cholesterol-fed dogs is shown in Fig. 6 , A and B, respectively. Rabbit Pevikon block fractions 1-3 had cholesterol/triglyceride ratios of 6.4, 3.5, and 0.76, respectively, whereas the corresponding canine fractions had cholesterol/triglyceride ratios of 20, 15, and 8, respectively. Thus, d < 1.006-g/ml lipoproteins from cholesterol-fed animals were, on the whole, much more cholesterolrich than those from human dys-f3 subjects. They were also rich in apo-E as shown by their E:C ratio (Table III) . All Pevikon block fractions had higher binding affinity for human apo-B,E(LDL) receptors than did human LDL and were similar in binding affinity to corresponding fractions from human atypical dys-j3 subjects (Table IV) . had higher binding affinity than did d < 1.006 g/ml lipoproerol-fed dogs. teins from normal subjects was surprising. On the other hand, Is are animal since apo-E from the atypical dys-3 subjects had higher affinity n. However, than apo-E from typical dys-13 subjects, it was not surprising imals studied that their d < 1.006 g/ml lipoproteins also had higher binding 1,000 mg/dl. affinity.
g/ml
In the current study, dys-f3 subjects with amino acid substitutions in apo-E at atypical sites (residues 142, 145, or 146) were found to have several features in common with typical dys-3 subjects. In all dys-13 subjects, the pre-f3-VLDL were larger, had higher flotation rates, and were more triglyceriderich than the smaller, more cholesteryl ester-rich f3-VLDL. The higher B48:B 100 ratio in pre-fl-VLDL than in #-VLDL agrees with other studies in which lipoproteins from the intestine were found to be larger and have higher flotation rates than those from the liver (27, (53) (54) (55) . dys-f subjects were 640-and 17-fold higher, respectively, than corresponding lipoproteins from typical dys-f subjects (Table   IV) . Another difference was that pre-,3-VLDL and #l-VLDL from atypical dys-f subjects had similar binding affinities, 1,000 10,000 whereas f3-VLDL from typical dys-# subjects had over 68-fold higher affinity than did their pre-f3-VLDL (27) . Since both pre-f3-VLDL and fl-VLDL from atypical dys-,B subjects had )g oining 1 high binding affinities, decreased binding affinity of pre-p-)ni(., EQg0 VLDL is not a major factor in the formation of fl-VLDL as = 12.6 ,g pro-may be the case in typical dys-# subjects (27) .
13 sg protein/ The d < 1.006 g/ml fractions from atypical dys-f3 subjects icentrations inhad higher affinity than did the d < 1.006 g/ml fractions from normolipidemic or hyperlipidemic subjects (27) or from unaf-fected members of family A. who were homozygous for normal apo-E3. In addition, the receptor binding studies performed using the whole plasma indicate that the average affinity of lipoproteins in atypical dys-fl subjects is sevenfold higher than in normal subjects (Fig. 5) . Thus, it is difficult to conclude that defective interaction of atypical dys-f lipoproteins with apo-B,E(LDL) receptors results in delayed clearance in vivo. When these lipoproteins were studied in vivo in cholesterol-fed rabbits, the clearance of '251-labeled apo-B in pre-3-VLDL and j3-VLDL from an atypical dys-j subject was much faster than that of '25I-labeled apo-B in corresponding lipoproteins from a typical dys-fl subject (unpublished observations). However, the clearance of these lipoproteins from the plasma of rabbits may not be the same as the clearance in humans.
What is the mechanism of the high binding affinity of d < 1.006-g/ml lipoproteins from atypical dys-fl subjects, and why do lipoproteins with high binding affinity accumulate in subjects with this disorder? First, the amino acid substitutions in apo-E from atypical dys-(3 subjects cause less defective binding to receptors than does the typical substitution at residue 158 (1, 5, 10) . Second, apo-E on native lipoproteins from subjects who were heterozygous for a substitution in apo-E at residue 142 or 146 was a mixture of both abnormal and normal apo-E. Finally, all d < 1.006 g/ml lipoproteins from the atypical dys-fi subjects contained relatively more apo-E than did corresponding lipoproteins from typical dys-/3 subjects (Table III) (Fig. 6 and Table IV ).
The only human in vivo study in which atypical and typical dys-fl subjects have been compared shows that the clearance of apo-B in d < 1.006-g/ml lipoproteins from dys-f3 subjects with an amino acid substitution in apo-E at 158 or 145 was similarly delayed (32) . However, this study did not discriminate between the three mechanisms for fl-VLDL accumulation described above. In the future, studies of in vivo apo-B kinetics of pre-fl-VLDL and j3-VLDL from atypical dys-j3 subjects may be useful to measure the rate of production of these lipoproteins. It is reasonable to speculate that the clearance of LDL in atypical dys-13 subjects may be slower than it is in typical dys-fl subjects due to competition for receptor binding by d < 1.006 g/ml lipoproteins with higher affinity than that of LDL or due to downregulation of apo-B,E(LDL) receptors. Direct measurement of the interaction between pre-fl-VLDL or f3-VLDL and hepatic tissue may reveal binding sites other than the apo-B,E(LDL) receptor and may also shed light on the pathogenesis of atypical dysbetalipoproteinemia.
A fascinating and unexplained feature of atypical dysbetalipoproteinemia is its apparent inheritance as an autosomal dominant trait in some families (9) (10) (11) 62) . Members of family A. in this study who did not have dysbetalipoproteinemia had a double pre-fl pattern, and some had hypercholesterolemia (Table I) . The subjects differently. More studies are needed to address these issues. In summary, the major finding in this study is that d < 1.006 g/ml lipoproteins from atypical dys-,3 subjects have paradoxically high affinity for apo-B,E(LDL) receptors. The accumulation of d < 1.006 g/ml lipoproteins in atypical dys-j3 subjects cannot be ascribed simply to low affinity for apo-B,E(LDL) receptors, as happens in typical dys-,3 subjects. Another explanation for the pathogenesis of atypical dysbetalipoproteinemia must be found. Although cholesterol-fed animals do not have a mutation in apo-E, they may serve as useful models for atypical dysbetalipoproteinemia because they also accumulate f3-VLDL by a mechanism other than decreased affinity of lipoproteins for apo-B,E(LDL) receptors. Since overproduction of d < 1.006 g/ml lipoproteins and downregulation of apo-B,E(LDL) receptors in these animals appear to cause the formation of f3-VLDL, a similar mechanism may be important in the pathogenesis of human atypical dysbetalipoproteinemia.
